Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to angioid streaks

Apte, Rajendra S.

doi:10.1038/sj.eye.6702941

Cited by 10 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3] The theoretical systemic risks of arterial thromboembolic events in the elderly that may be associated with intravitreal injection of antivascular endothelial growth factor therapy have been described 4-6 but have not deterred treatment because of the significant visual and functional gains that far exceed outcomes with the previous treatment modalities of thermal laser photocoagulation and photodynamic therapy. Intravitreal antivascular endothelial growth factor therapy is gaining acceptance as a beneficial treatment for choroidal neovascularization (CNV) from etiologies other than age-related macular degeneration, [7][8][9][10][11][12][13] cystoid macular edema associated with uveitis, 14,15 retinal vein occlusions, 16,17 and diabetic retinopathy. [18][19][20] These additional indications make the treatment of younger patients much more frequent.…”

mentioning

confidence: 99%

Intravitreal Bevacizumab During Pregnancy

Tarantola¹,

Folk²,

Boldt³

et al. 2010

Retina

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Intravitreal Bevacizumab During Pregnancy

Tarantola¹,

Folk²,

Boldt³

et al. 2010

Retina

View full text Add to dashboard Cite

show abstract

“…45 All reports indicate an improvement of vision in the short term (Table 3). [46][47][48][49][50][51][52][53][54] The longest followup is approximately 2 years (range: 3-24 months). There are several interesting trends among studies of angioid-streak-related CNV treatment with antiangiogenic agents.…”

Section: Therapeutic Optionsmentioning

confidence: 99%

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

Choroidal neovascularisation (CNV) is characterised by new blood vessel growth under the retina that usually results in significant visual impairment when the fovea is involved. Though CNV is more commonly associated with age-related macular degeneration (AMD), it can occur secondary to a variety of other diseases. Recent successes with anti-angiogenic therapies suggest that they may outperform other therapies for all types of CNV. As non-AMD-related CNV cases are rare, randomised controlled trials are often not possible. This review compares the less prevalent reports of non-AMD CNV and pools evidence on the success and limitations of a variety of therapies.

show abstract

“…Recently, intravitreally administrated bevacizumab , a vascular endothelial growth factor (VEGF) inhibitor that is a full size antibody to all isoforms of VEGF-A, has been successfully used as an off label treatment on CNV secondary to angioid streaks [1,17] . However, the current medical literature encompasses only few case reports of CNV associated with AS treated with bevacizumab (Bhatnagar et al2007;Apte 2008). Derriman et al (2008) [1 9] reported stability of VA for 6 months after three intravitreal injections of bevacizumab(1.25 mg) spaced at monthly intervals.…”

mentioning

confidence: 99%